Endothelial dysfunction inhibits the ability of haptoglobin to prevent hemoglobin-induced hypertension

In conclusion, in healthy C57Bl/6 mice with normal endothelium, coadministration of haptoglobin but not hemopexin with cell-free hemoglobin prevents acute hemoglobin-induced systemic hypertension by compartmentalizing cell-free hemoglobin in plasma. In murine diseases associated with endothelial dysfunction, haptoglobin therapy appears to be insufficient to prevent hemoglobin-induced vasoconstriction.
NEW & NOTEWORTHY Coadministraton of haptoglobin but not hemopexin with cell-free hemoglobin prevents hemoglobin-induced systemic hypertension in mice with a normal endothelium. In contrast, treatment with the same amount of haptoglobin is unable to prevent hemoglobin-induced vasoconstriction in mice with hyperlipidemia or diabetes mellitus, disorders that are associated with endothelial dysfunction.

Source: AJP: Heart and Circulatory Physiology - June 1, 2017 Category: Cardiology Authors: Graw, J. A., Yu, B., Rezoagli, E., Warren, H. S., Buys, E. S., Bloch, D. B., Zapol, W. M. Tags: RAPID REPORT Source Type: research